Ultragenyx Pharmaceutical Inc (MEX:RARE)
MXN 751.98 0 (0%) Market Cap: 65.87 Bil Enterprise Value: 59.05 Bil PE Ratio: 0 PB Ratio: 23.46 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 10:20PM GMT
Release Date Price: MXN887.76
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Great. Good afternoon, everyone. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. And we're really pleased to have Emil Kakkis, Founder, President and CEO of Ultragenyx.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

So Emil, it's been quite a few years since you founded this company; and you've emerged as a commercial story with a pipeline that continues to evolve. Just to level set, as you sit here today and you look at the commercial aspect and the pipeline and the modalities you brought in, where do you see kind of the future of Ultragenyx going?

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director

Well, first of all, I'm very happy, at 12 years, to be a commercial company with 4 approved products; to have 5 late-stage programs, which is hard to do; and then to be heading into $420 million, $450 million revenue this year. [So an]

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot